Category - Feature

Feature

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

Passage Bio (NASDAQ:PASG) is focused on developing transformative, differentiated therapies for rare, life-threatening monogenic CNS disorders, with the goal of mitigating development risk. “We believe that our rigorous...

June 30, 2020

Feature

CohBar developing therapeutics from mitochondrial DNA

CohBar (NASDAQ:CWBR) is transforming peptides encoded and expressed by mitochondria, some of which control a wide range of systems in the body, into novel therapeutics. “Harnessing the power of mitochondria biology to...

June 23, 2020

Feature

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal disease.

June 16, 2020

Feature

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

In his role as SVP of life sciences, Ian Koenig brings broad experience to Investis Digital in communications strategy, digital marketing, investor relations and business development on behalf of biopharma globally. Mr...

June 9, 2020

Feature

Chris Kaplan of ITG talks up market-making in capital markets

As a VP of Independent Trading Group (ITG), an issuer designated market making firm, Chris Kaplan brings a more institutional approach to provide liquidity for clients with stocks that are thinly traded. ITG, which is...

June 2, 2020

Feature

SetPoint Medical developing bioelectric treatment for RA, chronic autoimmune diseases

Closely-held SetPoint Medical is pioneering electric stimulation of the vagus nerve in the neck as a treatment for rheumatoid arthritis (RA) and other chronic autoimmune diseases, such as Crohn’s disease, ulcerative...

May 26, 2020

Feature

Spring Bank Pharma may expand R&D with potential COVID-19 agents

After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...

May 19, 2020

Feature

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic...

May 12, 2020

Feature

Eyenovia micro-array print therapeutics targeting various ophthalmic indications

Eyenovia (NASDAQ:EYEN) is using its unique microdose drug delivery technology, Optejet, to build a late-stage pipeline of ophthalmic therapeutics. “We have three late-stage programs for three major indications that we...

May 5, 2020

Feature

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device is helping to open a new front in the battle against COVID-19. “Optimal volume management and knowledge of capillary status is key to survivability...

April 28, 2020

Category - Feature

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

CohBar developing therapeutics from mitochondrial DNA

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

Chris Kaplan of ITG talks up market-making in capital markets

SetPoint Medical developing bioelectric treatment for RA, chronic autoimmune diseases

Spring Bank Pharma may expand R&D with potential COVID-19 agents

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Eyenovia micro-array print therapeutics targeting various ophthalmic indications

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

General

More